Last updated: July 15, 2021
Sponsor: Ruijin Hospital
Overall Status: Active - Not Recruiting
Phase
3
Condition
Chemotherapy
Stomach Cancer
Digestive System Neoplasms
Treatment
N/AClinical Study ID
NCT04384601
Dragon III-Phase 3
Ages 18-80 All Genders
Study Summary
Eligibility Criteria
Inclusion
Inclusion Criteria:
- Histology confirmed non-obstructive adenocarcinoma of stomach or esophago-gastricjunction.
- Clinical stage: Clinical Tumor-Node-Metastasis (cTNM:) stage III
- Performance status: Eastern Cooperative Oncology Group (ECOG) ≤ 2 (normal tosymptomatic but in bed less than half the day)
- Clinically fit for systemic chemotherapy and gastric cancer surgery, i.e. adequaterenal, hepatic, hematologic and pulmonary function.
- Written informed consent
Exclusion
Exclusion Criteria:
- Clinically unfit for systemic chemotherapy and gastric cancer surgery, i.e.uncontrolled cardiac disease, or other clinically significant uncontrolledcomorbidities, unable to undergo general anesthesia
- Distant metastases (including retroperitoneal lymph node)
- Locally advanced inoperable disease (Clinical assessment)
- Relapse of gastric cancer
- Malignant secondary disease
- Prior chemo or radio therapy
- Inclusion in another clinical trial
- Known contraindications or hypersensitivity for planned chemotherapy
Study Design
Total Participants: 246
Study Start date:
September 01, 2021
Estimated Completion Date:
September 30, 2027
Study Description
Connect with a study center
Ruijin Hospital Shanghai Jiaotong University School of Medicine
Shanghai, Shanghai 200025
ChinaSite Not Available

Not the study for you?
Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.